Johanna Holldack
Direttore/Membro del Consiglio presso PHOTOCURE ASA
Patrimonio netto: - $ in data 30/04/2024
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Madiha Derouazi | M | 51 |
Amal Therapeutics SA
 Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | 12 anni |
| Erik Dahl | M | - | 12 anni | |
| Neal Shore | M | - | 2 anni | |
| Dylan Hallerberg | M | - | - | |
| Daniel Schneider | M | - | 6 anni | |
| Anders Neijber | M | - | 3 anni | |
| Patricia Kelly | F | - | 4 anni | |
| Susanne Strauss | M | - | 4 anni | |
| Andreas Wallnöfer | M | 63 |
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | - |
| Karin Hehenberger | M | 52 |
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | - |
| Pierre Armand Morgon | M | 61 |
Kupando GmbH
 Kupando GmbH BiotechnologyHealth Technology Kupando GmbH is a German biopharmaceutical company that develops agonists to stimulate innate immunity. The company is based in Schoenefeld, Germany. The company was founded in 2018 by Johanna Holldack, who has been the CEO since 2018. | 3 anni |
| Malene Brondberg | F | 51 | - | |
| Frank Kalkbrenner | M | - |
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | - |
| Grete Hogstad | F | 68 | 19 anni | |
| Geoffrey Coy | M | - | 5 anni | |
| Roberto Maj | M | - |
Kupando GmbH
Kupando GmbH BiotechnologyHealth Technology Kupando GmbH is a German biopharmaceutical company that develops agonists to stimulate innate immunity. The company is based in Schoenefeld, Germany. The company was founded in 2018 by Johanna Holldack, who has been the CEO since 2018. | - |
| Maja Bergmann | F | - | 5 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Kjetil Hestdal | M | 64 | 21 anni | |
| Gwen Melincoff | M | 72 | 3 anni | |
| Tom Edward Pike | M | 64 | 6 anni | |
| Jan Hendrik Egberts | M | 65 | 6 anni | |
| Synne Hermansen Røine | F | 45 | 6 anni | |
| Anne Hovi Worsøe | F | 60 | - | |
| Gry Stensrud | M | 54 | 15 anni | |
| Anders Tuv | M | 46 | - | |
| Jeremy Bahr | M | - | - | |
| Kari Myren | F | - | 6 anni | |
| Einar Antonsen | M | - | 1 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Norvegia | 22 | 78.57% |
| Svizzera | 4 | 14.29% |
| Germania | 2 | 7.14% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Johanna Holldack
- Contatti personali
